Sai Bo Song is being developed as an opioid dependence treatment. Credit: Find Rehab Centers/Flickr.

Specialty pharmaceutical company Indivior has agreed to sell its rights to Sai Bo Song (buprenorphine, naloxone) tablet in China to Zhejiang Pukang Biotechnology for up to $122.5m.

Sai Bo Song is being developed as an opioid dependence treatment. The sale is part of the company’s strategy to focus on its new products, Sublocade and Perseris.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The deal is subject to Sai Bo Song’s designation as a Class II psychotropic drug by Chinese regulators, as well as other approvals and closing conditions.

Under the terms of a definitive agreement, Indivior will receive a signing payment of $1.5m, $3.5m upon the designation of Sai Bo Song and $12.5m at the time of closing of the transaction.

The company may additionally receive $105m depending on assistance provided to Pukang and on reaching select sales milestones during a ten-year period after the first commercial sale of the medicine in China.

“This transaction helps us focus our resources on the highest return opportunities in the regions we know best, while ensuring patients in China have access to an important and transformational treatment.”

Indivior CEO Shaun Thaxter said: “The divestiture of the Sai Bo Song tablet in China is consistent with Indivior’s efforts to prioritise efforts on the long-term growth opportunities with our new depot assets, Sublocade and Perseris.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“This transaction helps us focus our resources on the highest return opportunities in the regions we know best, while ensuring patients in China have access to an important and transformational treatment.”

Furthermore, the company entered into an agreement with US-based drugmaker Alvogen Pine Brook, which temporarily prohibits the latter from selling, using, offering to sell or importing generic versions of buprenorphine and naloxone sublingual film product, Indivior’s opioid dependence therapy.

Last month, a US district court granted a temporary restraining order against Alvogen, stopping the company from launching the generic versions.